Follows adults with ulcerative colitis or Crohn's disease taking upadacitinib in Belgium
Observes how upadacitinib works in adults with ulcerative colitis or Crohn's disease.
Plain-language title generated from the registry record
Registry title: Study to Assess Treatment Patterns and Outcomes With Upadacitinib in Adult Participants With Inflammatory Bowel Disease in Belgium
Key facts
- Where
- Anderlecht, Bonheiden, Genk, Ghent, Kortrijk, Liège, Lodelinsart, Roeselare, Sint-Niklaas, and Tournai, BelgiumSee the 11 sites
Where in Belgium
- Universite Libre de Bruxelles - Hopital Erasme /ID# 268632Anderlecht, BelgiumTaking people
- Imelda Ziekenhuis /ID# 268631Bonheiden, BelgiumTaking people
- Ziekenhuis Oost-Limburg, Campus St.-Jan /ID# 283334Genk, BelgiumTaking people
- UZ Gent /ID# 268630Ghent, BelgiumTaking people
- AZ Groeninge /ID# 268638Kortrijk, BelgiumTaking people
- CHU de Liege /ID# 267209Liège, BelgiumTaking people
- Groupe Sante CHC - Clinique du MontLegia /ID# 268662Liège, BelgiumTaking people
- Chu De Charleroi - Hopital Civil Marie Curie /ID# 284063Lodelinsart, BelgiumTaking people
- AZ-Delta. /ID# 283323Roeselare, BelgiumTaking people
- Vitaz /Id# 268637Sint-Niklaas, BelgiumTaking people
- Centre Hospitalier De Wallonie Picarde - Site Notre Dame /ID# 284064Tournai, BelgiumTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- AbbVie
- Trial code
- NCT06581042
- Record updated
- 23 September 2026
- Original description
Crohn's disease (CD) is an incurable chronic inflammatory disorder of the gastrointestinal tract. Ulcerative colitis (UC) is an idiopathic, chronic, inflammatory disease affecting the colon. This study will assess the (long-term) effectiveness and safety of upadacitinib in real-world clinical practice in adult participants with moderate to severe ulcerative colitis (UC) and crohn's disease (CD).Read full original descriptionShow less
Understanding Local TReatment Patterns and Outcomes With upAdacitinib in IBD Patients in Belgium
Crohn's disease (CD) is an incurable chronic inflammatory disorder of the gastrointestinal tract. Ulcerative colitis (UC) is an idiopathic, chronic, inflammatory disease affecting the colon. This study will assess the (long-term) effectiveness and safety of upadacitinib in real-world clinical practice in adult participants with moderate to severe ulcerative colitis (UC) and crohn's disease (CD).
Upadacitinib is an approved drug for treating ulcerative colitis (UC) and Crohn's disease (CD). Approximately 280 participants who are prescribed Upadacitinib by their physician in accordance with local label will be enrolled in 8 sites across Belgium.
Participants will receive upadacitinib as prescribed by their physician according to their routine clinical practice and local label. Participants will be followed for up to 3 years.
There is expected to be no additional burden for participants in this trial. Participants will attend regular visits during the study at a hospital or clinic according to their routine clinical practice
Inclusion: Participants with a diagnosis of moderate to severe Crohn's disease or Ulcerative colitis, initiated with upadacitinib at least 12 months prior to inclusion, including participants that were initiated on upadacitinib, but later (i.e. at the moment of data collection) discontinued, or switched to another treatment; Participants initiating commercially available upadacitinib at the clinician's discretion as part of their routine clinical care; the decision to administer upadacitinib must be made prior to and independent of recruitment into the study; Participants prescribed upadacitinib in accordance with the approved local label and treatment recommendations.
Exclusion: Participants previously exposed to upadacitinib in a clinical trial or early access program; Participants participating in interventional research (not including non-interventional; Participants with stoma.